OBJECTIVE: The objective of this study was to detail the epidemiologic characteristics and natural history of HIV-1 natural viral suppressors (NVSs), a cohort of HIV-1-infected individuals who are able to suppress viral replication to undetectable levels in the absence of therapy. DESIGN AND METHODS: HIV-1 patients who met the NVS criteria were enrolled into a prospective study. The incidence and prevalence of NVS were calculated by performing a chart review on all patients seen in 1 clinic in a 10-year period. Cumulative probability of progression-free survival was calculated by Kaplan-Meier product limit method. RESULTS: Forty individuals enrolled in the study. The median year of diagnosis was 1994, and individuals demonstrated a median 6.7 years of HIV-1 viral suppression and CD4 count of 795 cells per microliter. NVS had an incidence of 1.1% [95% confidence interval (CI), 0.0 to 2.1] and prevalence of 1.5% (95% CI, 0.8 to 2.1). Only 1 patient (2.5%) has progressed. Within the first 10 years for follow-up having met the definition of NVS, 95.1% (95% CI 86.5% to 100%) of the NVS continued to control their viral loads to undetectable levels. CONCLUSIONS: The NVS cohort has demonstrated remarkable stability and a low rate of progression over many years. Detailed evaluations of viral-host immune regulatory factors associated with persistent HIV-1 natural viral suppression, and loss of such suppression, has the potential to provide important new insight in HIV pathogenesis and future immune regulatory targeted preventive and therapeutic research.
OBJECTIVE: The objective of this study was to detail the epidemiologic characteristics and natural history of HIV-1 natural viral suppressors (NVSs), a cohort of HIV-1-infected individuals who are able to suppress viral replication to undetectable levels in the absence of therapy. DESIGN AND METHODS: HIV-1patients who met the NVS criteria were enrolled into a prospective study. The incidence and prevalence of NVS were calculated by performing a chart review on all patients seen in 1 clinic in a 10-year period. Cumulative probability of progression-free survival was calculated by Kaplan-Meier product limit method. RESULTS: Forty individuals enrolled in the study. The median year of diagnosis was 1994, and individuals demonstrated a median 6.7 years of HIV-1 viral suppression and CD4 count of 795 cells per microliter. NVS had an incidence of 1.1% [95% confidence interval (CI), 0.0 to 2.1] and prevalence of 1.5% (95% CI, 0.8 to 2.1). Only 1 patient (2.5%) has progressed. Within the first 10 years for follow-up having met the definition of NVS, 95.1% (95% CI 86.5% to 100%) of the NVS continued to control their viral loads to undetectable levels. CONCLUSIONS: The NVS cohort has demonstrated remarkable stability and a low rate of progression over many years. Detailed evaluations of viral-host immune regulatory factors associated with persistent HIV-1 natural viral suppression, and loss of such suppression, has the potential to provide important new insight in HIV pathogenesis and future immune regulatory targeted preventive and therapeutic research.
Authors: A R Garbuglia; R Salvi; A Di Caro; G Cappiello; F Montella; F Di Sora; O Recchia; F Lauria; A Benedetto Journal: AIDS Date: 1996-01 Impact factor: 4.177
Authors: S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors Journal: Proc Natl Acad Sci U S A Date: 2000-03-14 Impact factor: 11.205
Authors: G Pantaleo; S Menzo; M Vaccarezza; C Graziosi; O J Cohen; J F Demarest; D Montefiori; J M Orenstein; C Fox; L K Schrager Journal: N Engl J Med Date: 1995-01-26 Impact factor: 91.245
Authors: Adriana Andrade; Justin R Bailey; Jie Xu; Frances H Philp; Thomas C Quinn; Thomas M Williams; Stuart C Ray; David L Thomas; Joel N Blankson Journal: Clin Infect Dis Date: 2008-04-15 Impact factor: 9.079
Authors: M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien Journal: Science Date: 1996-09-27 Impact factor: 47.728
Authors: Berta Rodés; Carlos Toro; Ellen Paxinos; Eva Poveda; Manuel Martinez-Padial; José Miguel Benito; Victoria Jimenez; Terri Wrin; Sylvina Bassani; Vincent Soriano Journal: AIDS Date: 2004-05-21 Impact factor: 4.177
Authors: L Wu; W A Paxton; N Kassam; N Ruffing; J B Rottman; N Sullivan; H Choe; J Sodroski; W Newman; R A Koup; C R Mackay Journal: J Exp Med Date: 1997-05-05 Impact factor: 14.307
Authors: Karen A O'Connell; Timothy P Brennan; Justin R Bailey; Stuart C Ray; Robert F Siliciano; Joel N Blankson Journal: J Virol Date: 2010-05-05 Impact factor: 5.103
Authors: Mohammad Mohseni Sajadi; Amir Dashti; Zahra Rikhtegaran Tehrani; William D Tolbert; Michael S Seaman; Xin Ouyang; Neelakshi Gohain; Marzena Pazgier; Dongkyoon Kim; Guy Cavet; Jean Yared; Robert R Redfield; George K Lewis; Anthony L DeVico Journal: Cell Date: 2018-05-03 Impact factor: 41.582
Authors: Mohammad M Sajadi; Yongjun Guan; Anthony L DeVico; Michael S Seaman; Mian Hossain; George K Lewis; Robert R Redfield Journal: J Acquir Immune Defic Syndr Date: 2011-05-01 Impact factor: 3.731
Authors: Yongjun Guan; Mohammad M Sajadi; Roberta Kamin-Lewis; Timothy R Fouts; Anthony Dimitrov; Zhixin Zhang; Robert R Redfield; Anthony L DeVico; Robert C Gallo; George K Lewis Journal: Proc Natl Acad Sci U S A Date: 2009-02-18 Impact factor: 11.205
Authors: Yongjun Guan; Marzena Pazgier; Mohammad M Sajadi; Roberta Kamin-Lewis; Salma Al-Darmarki; Robin Flinko; Elena Lovo; Xueji Wu; James E Robinson; Michael S Seaman; Timothy R Fouts; Robert C Gallo; Anthony L DeVico; George K Lewis Journal: Proc Natl Acad Sci U S A Date: 2012-12-13 Impact factor: 11.205
Authors: Lindsay M Eyzaguirre; Manhattan Charurat; Robert R Redfield; William A Blattner; Jean K Carr; Mohammad M Sajadi Journal: Virology Date: 2013-06-19 Impact factor: 3.616
Authors: David J Riedel; Mohammad M Sajadi; Cheryl L Armstrong; Jean-Saville Cummings; Cristiana Cairo; Robert R Redfield; C David Pauza Journal: AIDS Date: 2009-09-24 Impact factor: 4.177
Authors: Clarisa M Buckner; Lela Kardava; Xiaozhen Zhang; Kathleen Gittens; J Shawn Justement; Colin Kovacs; Adrian B McDermott; Yuxing Li; Mohammad M Sajadi; Tae-Wook Chun; Anthony S Fauci; Susan Moir Journal: J Infect Dis Date: 2016-04-27 Impact factor: 5.226